NA
HRTX icon

NewEdge Advisors’s Heron Therapeutics HRTX Stock Holding History

NewEdge Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,187
Closed -$35.5K – 4294
2025
Q3 		$35.5K Buy
28,187
+1,618
+6% +$2.56K ﹤0.01% 2931
2025
Q2 		$55K Buy
26,569
+19
+0.1% +$39 ﹤0.01% 2637
2025
Q1 		$58.4K Hold
26,550
– – ﹤0.01% 2495
2024
Q4 		$40.6K Hold
26,550
– – ﹤0.01% 2587
2024
Q3 		$52.8K Buy
+26,550
New +$63.4K ﹤0.01% 2413
2023
Q4 		– Sell
-2,800
Closed -$2.88K – 3805
2023
Q3 		$2.88K Hold
2,800
– – ﹤0.01% 2967
2023
Q2 		$3.25K Hold
2,800
– – ﹤0.01% 2954
2023
Q1 		$4.23K Buy
2,800
+1,400
+100% +$3.51K ﹤0.01% 2837
2022
Q4 		$4 Buy
+1,400
New +$4.51K ﹤0.01% 3844

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

NewEdge Advisors's HRTX Position: Q4 2025 in Review

NewEdge Advisors sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 28,187 shares — an estimated $35.5K sold.

NewEdge Advisors first reported a position in HRTX in Q4 2022 and held it in 9 quarters. The position peaked at $58.4K in Q1 2025. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • NewEdge Advisors reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 28,187 Heron Therapeutics shares in Q4 2025, an estimated $35.5K.
  • NewEdge Advisors first reported a position in Heron Therapeutics in Q4 2022 and held it in 9 quarters.
  • NewEdge Advisors's Heron Therapeutics position peaked at $58.4K in Q1 2025.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.